References

The Incretin System: Glucagon‐Like Peptide‐1 Receptor Agonists and Dipeptidyl Peptidase‐4 Inhibitors in Type 2 Diabetes

10.1016/s0140-6736(06)69705-5 · 2006 · External reference

The Different Colorectal Tumor Risk Related to GLP‐1 Receptor Agonists and SGLT2 Inhibitors Use: A Network Meta‐Analysis of 68 Randomized Controlled Trials

10.1097/js9.0000000000003450 · 2026 · External reference

Molecular Engineering of Designer Diabetes Therapeutics

10.1016/j.jconrel.2026.114705 · 2026 · External reference

Long‐Acting GIPR Agonist LY3537021 Reduces Body Weight and Fasting Blood Glucose in Patients With T2D: Preclinical Development and Phase 1 Randomized Ascending Dose Studies

10.1016/j.molmet.2025.102298 · 2026 · External reference

Absorption, Metabolism and Excretion of the GLP‐1 Analogue Semaglutide in Humans and Nonclinical Species

10.1016/j.ejps.2017.03.020 · 2017 · External reference

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Renal Impairment

10.1007/s40262-018-0649-2 · 2018 · External reference

Discovery of the Once‐Weekly Glucagon‐Like Peptide‐1 (GLP‐1) Analogue Semaglutide

10.1021/acs.jmedchem.5b00726 · 2015 · External reference

Evaluating the Efficacy, Safety, and Practical Considerations of Semaglutide for Weight Loss in Non‐Diabetic Adults: A Narrative Review

10.1002/hsr2.72144 · 2026 · External reference

Approved Weight Loss Drugs for Obesity With a Thorough Emphasis on GLP‐1 Agonist Medications: A Systematic Review

10.1016/j.disamonth.2026.102113 · 2026 · External reference

Semaglutide‐Associated Acute Pancreatitis in a Patient With Type 2 Diabetes Mellitus: A Case Report

2026 · External reference

GLP‐1 Receptor Agonist‐Associated Eosinophilic Duodenitis Presenting as a Bowel Obstruction: A Case Report and Literature Review

10.51821/89.1.14613 · 2026 · External reference

From Weight Loss to Muscle Loss: Rhabdomyolysis Linked to Semaglutide

10.1093/ckj/sfaf356 · 2025 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Investigations Into the Human Metabolism of Trestolone (7alpha‐Methyl‐19‐Nortestosterone)

10.1002/dta.70018 · 2026 · External reference

Clostebol Metabolism by Different Routes of Administration: Selection of Diagnostic Urinary Markers

10.1002/dta.3953 · 2025 · External reference

A Computational Integration Strategy Driven by Chemical Similarity Uncovers Comprehensive Metabolic Profiles of Small Bioactive Peptides via UHPLC‐HRMS for Doping Control

10.1021/acs.analchem.5c04272 · 2025 · External reference

Metabolic Profile Characterization of Voxelotor in Human Urine Based on In Vivo and In Vitro Models for Doping Control

10.1007/s00216-024-05555-8 · 2024 · External reference

Identification of Semaglutide Use Through Detection of U6 and U7 Metabolites in Human Urine

10.1007/s00216-025-06263-7 · 2026 · External reference

Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP‐1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects With Type 2 Diabetes

10.1007/s40262-018-0728-4 · 2019 · External reference

The Development of an Oral GLP‐1 Receptor Agonist for the Management of Type 2 Diabetes: Evidence to Date

10.2147/dddt.s166765 · 2019 · External reference

Efficacy and Safety in a Real‐World Study of the New Oral Formulation of Semaglutide in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus

10.3390/jcm13175166 · 2024 · External reference

Pharmacokinetics and Clinical Implications of Oral Semaglutide for Type 2 Diabetes Mellitus

10.1007/s40262-020-00951-6 · 2021 · External reference

Systemic Pharmacokinetic Principles of Therapeutic Peptides

10.1007/s40262-025-01615-z · 2026 · External reference

Absorption, Distribution, Metabolism, and Excretion of Tirzepatide in Humans, Rats, and Monkeys

10.1016/j.ejps.2024.106895 · 2024 · External reference

Unresolved reference

External reference

Comprehensive Metabolic Characterization of GBT1118 in Humans Using a Combined Approach via UHPLC‐HRMS for Doping Control

10.1007/s00216-026-06478-2 · 2026 · External reference

Relationship Between Oral Semaglutide Tablet Erosion and Pharmacokinetics: A Pharmacoscintigraphic Study

10.1002/cpdd.938 · 2021 · External reference

Development and Approval of Rybelsus (Oral Semaglutide): Ushering in a New Era in Peptide Delivery

10.1007/s13346-021-01000-w · 2022 · External reference

A Review of the Oral Semaglutide in Adults With Overweight or Obesity (OASIS) Trials Evaluating Oral Semaglutide (Wegovy) for Chronic Weight Management in Adults With Overweight or Obesity

2026 · External reference